[Immunotherapeutic treatment for metastatic renal carcinoma]

Immunotherapy management for advanced renal carcinoma has awaken a growing interest over the last few years. Based on Atzpodien's studies, in December 1994 a protocol was initiated in our centre for the treatment of metastatic renal carcinoma, using subcutaneous alpha interferon, subcutaneous Interleukin-2 and endovenous 5-Fluorouracil. The present report analyzes all six cases included in the protocol and their results.